Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 14, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: High Cholesterol Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol

NCT00762164
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Vytorin, Simvastatin
Drug
Lead sponsor
Bronx VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)

NCT02722408
View directory record Official record
Conditions
Hypercholesteremia
Interventions
Gemcabene
Drug
Lead sponsor
NeuroBo Pharmaceuticals Inc.
Industry
Eligibility
17 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of REGN727/SAR236553 in Patients With HeFH Hypercholesterolemia

NCT01266876
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Alirocumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
17
States / cities
Huntsville, Alabama • Mission Viejo, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly

NCT00127218
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Disease
Interventions
any statin, niacin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

NCT01058083
View directory record Official record
Conditions
Dyslipidemia
Interventions
BMS-770767, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Little Rock, Arkansas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

NCT00570739
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
Interventions
Metformin HCl and Colesevelam Placebo, Metformin HCl tablets and Colesevelam tablets, Colesevelam placebo, Colesevelam
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 79 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Gatos, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2010 · Synced Sep 14, 2026, 4:37 AM EDT
Recruiting Not applicable Interventional

Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence

NCT06374277
View directory record Official record
Conditions
Diabetes, Hypertension, High Cholesterol/Hyperlipidemia, Coronary Artery Disease, Congestive Heart Failure, Chronic Lung Disease, Chronic Kidney Diseases, Arrythmia, Stroke, Depression, Anxiety, Pulmonary Embolism, Heart Attack
Interventions
Med AAAction intervention
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Knoxville, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 14, 2026, 4:37 AM EDT
Recruiting Phase 3 Interventional

Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies

NCT05682378
View directory record Official record
Conditions
Heterozygous or Homozygous Familial Hypercholesterolemia
Interventions
Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 100 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
5
States / cities
Boca Raton, Florida • New York, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Not applicable Interventional

Improving Diagnosis and Clinical Management of Familial Hypercholesterolemia Through Integrated Machine Learning, Implementation Science, and Behavioral Economics

NCT05746247
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Testing centralized referral mechanism for PCPs, Inviting patients to complete a telehealth appointment with a lipid specialist for an FH evaluation
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

NCT01342211
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
Placebo, Statin, PF-04950615 (RN316), Satin
Biological · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
38
States / cities
Tustin, California • Walnut Creek, California • Clearwater, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2017 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia

NCT02833844
View directory record Official record
Conditions
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Interventions
Evolocumab, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
20
States / cities
Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 14, 2026, 4:37 AM EDT
Terminated Phase 3 Interventional

Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia

NCT00249899
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Lapaquistat acetate and stable statin therapy, Stable statin therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
649 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Santa Ana, California • Chicago, Illinois • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated May 23, 2012 · Synced Sep 14, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional

Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy

NCT00079846
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
Implitapide
Drug
Lead sponsor
Medical Research Laboratories International
Industry
Eligibility
8 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis

NCT00983983
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Oxepa, Jevity 1.5, Jevity 1.0
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease

NCT00706849
View directory record Official record
Conditions
Heterozygous Familial Hypercholesterolemia, Coronary Artery Disease
Interventions
mipomersen sodium, placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
37
States / cities
La Jolla, California • Los Angeles, California • Mission Viejo, California + 31 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance

NCT01751984
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Hartford, Connecticut • Indianapolis, Indiana • Raleigh, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 14, 2026, 4:37 AM EDT
Active, not recruiting Phase 3 Interventional

Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes

NCT06008756
View directory record Official record
Conditions
Arteriosclerosis, Hypercholesterolaemia
Interventions
Enlicitide Decanoate, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
14,550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
132
States / cities
Alexander City, Alabama • Birmingham, Alabama • Daphne, Alabama + 113 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 2 Interventional

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

NCT00701883
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Placebo, MBX-8025, Atorvastatin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2015 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

NCT03399370
View directory record Official record
Conditions
ASCVD, Elevated Cholesterol
Interventions
Inclisiran Sodium, Placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
1,561 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
145
States / cities
Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Therapy to Elevate CD4 Counts in HIV-1 Disease

NCT01370018
View directory record Official record
Conditions
HIV Disease
Interventions
alpha-1-Proteinase Inhibitor
Biological
Lead sponsor
Institute for Human Genetics and Biochemistry
Other
Eligibility
30 Years to 70 Years · Male only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Not applicable Interventional

Improved Cardiovascular Risk Reduction to Enhance Rural Primary Care

NCT01983813
View directory record Official record
Conditions
Diabetes Mellitus, Hypertension, Coronary Artery Disease, Atrial Fibrillation, Stroke
Interventions
PHCVRS Intervention, Personal Health Record
Other
Lead sponsor
Korey Kennelty
Other
Eligibility
50 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Akron, Iowa • Belmond, Iowa • Cedar Rapids, Iowa + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

NCT01849497
View directory record Official record
Conditions
Primary Hypercholesterolemia, Mixed Dyslipidemia
Interventions
Evolocumab Pre-filled Syringe, Evolocumab AI/pen
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
21
States / cities
Encino, California • Thousand Oaks, California • Ventura, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound

NCT01813422
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Evolocumab, Placebo
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
59
States / cities
Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Sep 14, 2026, 4:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Habitual Diet and Avocado Trial

NCT03528031
View directory record Official record
Conditions
Intra-abdominal Fat, Metabolic Syndrome, High Cholesterol, Triglycerides High, Diet Habit, High Blood Sugar, Liver Fat, Dietary Modification, HDL Cholesterol, Low Serum, Cardiovascular Diseases, High Density Lipoprotein Deficiency, Low-density-lipoprotein-type, Cardiovascular Risk Factor, Diabetes
Interventions
Intervention Daily Avocado
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years and older
Enrollment
1,008 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
4
States / cities
Loma Linda, California • Los Angeles, California • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Sep 14, 2026, 4:37 AM EDT